On Friday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) opened lower -4.54% from the last session, before settling in for the closing price of $11.68. Price fluctuations for DNA have ranged from $5.00 to $16.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -27.97%. Company’s average yearly earnings per share was noted 50.15% at the time writing. With a float of $40.51 million, this company’s outstanding shares have now reached $43.82 million.
Ginkgo Bioworks Holdings Inc (DNA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ginkgo Bioworks Holdings Inc is 27.92%, while institutional ownership is 58.35%. The most recent insider transaction that took place on Aug 22 ’25, was worth 3,843. In this transaction an insider of this company sold 310 shares at a rate of $12.40, taking the stock ownership to the 11,112 shares. Before that another transaction happened on Aug 06 ’25, when Company’s Officer proposed sale 2,200 for $14.10, making the entire transaction worth $31,020.
Ginkgo Bioworks Holdings Inc (DNA) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -1.08 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -3.32) by 2.24. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.27 per share during the current fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Check out the current performance indicators for Ginkgo Bioworks Holdings Inc (DNA). In the past quarter, the stock posted a quick ratio of 5.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.85, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -4.35 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Compared to the last year’s volume of 1.54 million, its volume of 1.91 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 25.62%.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 52.21%, which indicates a significant increase from 17.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.00 in the past 14 days, which was higher than the 0.83 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.04, while its 200-day Moving Average is $9.72. Nevertheless, the first resistance level for the watch stands at $11.48 in the near term. At $11.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.30. If the price goes on to break the first support level at $10.66, it is likely to go to the next support level at $10.18. Should the price break the second support level, the third support level stands at $9.84.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
There are currently 59,200K shares outstanding in the company with a market cap of 660.08 million. Presently, the company’s annual sales total 227,040 K according to its annual income of -547,030 K. Last quarter, the company’s sales amounted to 49,600 K and its income totaled -60,300 K.
